Your GLP-1 Program Was Never Selling the Drug

Go look at what your patient can see. Novo Nordisk publishes its self-pay prices on a public page, no login, no insurance, no prior authorization. As of this writing, the oral form of Wegovy starts at $149 a month, the injectable pen settles at $349 after an introductory period, and Medicare-eligible patients can get to $50.

Your patient can find that page in about eleven seconds.

I have watched a lot of independent practices build weight-loss revenue over the past three years, and a meaningful share of them built it on access. Access to a molecule that was hard to get, expensive through normal channels, and available through you. That was a real business while it lasted. It is not a business anymore, and the thing that ended it was not a competitor down the street. It was the manufacturer deciding to sell direct.

The strategic question is not whether to keep offering GLP-1s. It is whether you ever knew what you were charging for.

The price you are competing against is published

Start with the actual numbers, because most owners I talk to are working from a price they heard about eighteen months ago.

According to Novo Nordisk's own self-pay pharmacy page, which I re-read on the day I finished this piece, the Wegovy pill starts at $149 per month for the 1.5 mg dose, with 4 mg at $199 and the 9 mg and 25 mg doses at $299. The injectable pen is offered at $199 a month for a new patient's first two months, then $349 a month for standard doses and $399 for the 7.2 mg version. Medicare-eligible patients have a stated $50 per month pathway. The page states that pricing will be updated after December 31, 2026.

Three things in that paragraph matter more than the headline number.

The first is the oral formulation. An injectable creates a small but real barrier: some patients will not do needles, and the ones who will often want someone to show them how the first time. A pill removes the last practical reason a motivated, price-sensitive patient needs a clinical setting to start.

The second is that date. Pricing updates after December 31, 2026, and the schedule already moved once while this piece was being written. When I first pulled these figures on August 31, the 4 mg oral dose was listed at the same $149 as the starting dose and flagged as available only through that day. It now lists at $199. If your program's price is set relative to the drug's price, you are not running a pricing strategy. You are running a subscription to somebody else's pricing committee, and it re-prices without consulting you.

The third is the shape of the pen price. A new patient pays $199 for two months, then $349 from the third, a step-up of roughly 75 percent at exactly the point most patients are still climbing the dose schedule. You did not build that cliff and cannot smooth it, but you will be the one talking a patient through it.

What your program actually sells

Here is the exercise I would run before touching your price list. Write down everything a patient receives from your weight-loss program. Then cross off every line the manufacturer's direct channel also provides.

What is left is your actual product. For most physician-led practices it is a short list, and it is a good one.

I pulled the program description from a physician-led practice we work with in Michigan, because it is a clean example of a program that was built as medicine rather than as distribution. What a patient gets there: a full evaluation covering health history, current medications, labs, and goals before anything is prescribed. Dose started low and titrated gradually to limit side effects. Ongoing lab monitoring. Screening for contraindications, including thyroid and pancreatitis risk. Access to the physician throughout for dose adjustments. Tirzepatide available as an alternative if semaglutide is the wrong fit.

Their own page draws the line explicitly: this is not a prescription that arrives in the mail with no follow-up.

That distinction is not a marketing preference. It is where the failure actually happens. A 2025 study in the journal Obesity followed 15,811 commercially insured US adults on semaglutide for weight management. Most deviated from the recommended dose-escalation schedule inside five months, and 46 percent had discontinued by month five, holding at 48 percent among those who started after the shortages resolved. Discontinuation tracked cost too, rising from 41 percent in the lowest copayment quintile to 51 percent in the highest.

Read that as an operator. Nearly half the people who start this drug stop within five months, and the two factors most visible in the data are cost and a titration schedule they did not follow. The direct channel fixes the first. It does not touch the second.

That practice can survive $149 pills, because none of what I just listed is in the box. The mail-order channel ships a molecule. It does not check your thyroid, it does not adjust your dose when you cannot keep food down in week three, and it does not notice when the weight comes off too fast.

The practices that cannot survive it are the ones whose program was a prescription, a scale, and a monthly refill. If that describes yours, the direct channel is not a threat on the horizon. It is a strictly better version of what you sell, at a price you cannot match, and no amount of marketing fixes a product that has been made redundant.

The test I would run this week

There is a single question that sorts practices into the two groups, and it takes ten minutes.

Ask yourself what happens to your weight-loss program if the drug's price goes to zero.

If the answer is that the program collapses, you were selling distribution and the market has already repriced you. If the answer is that the program continues largely intact, because patients are paying for evaluation, titration, monitoring, and a physician who knows their history, then the drug's price is an input cost and you have been running a real service the whole time. In that case the direct channel is not your competitor. It is your supplier getting cheaper, which is a thing you should be pleased about.

Most owners have never separated those two revenue streams on paper, which is why the question lands hard. The medication and the medical management get billed as one number, so nobody knows the split.

You now have an external benchmark for one half of it. The direct channel prices the molecule between $149 and $349 a month depending on formulation, so whatever you charge above that figure, per patient per month, is what the market is currently willing to call your medical care. In my work with practices, running that subtraction is the first time most owners see their own service priced apart from their supply, and the remainder is usually smaller than they expected. That is not a reason to despair. It is the first honest number you have had on this line of business.

The generalizable lesson, and the reason I would not file this under weight loss: any revenue line whose differentiator is access to a product is a revenue line the product's owner can reclaim whenever the economics suit them. That is true of peptides, it is true of hormone therapy, and it will be true of whatever the next conference floor is excited about. Access is a rented advantage. Clinical judgment is an owned one.

What to do about it

Four moves, in order.

First, unbundle your pricing internally. Separate what you charge for the medication from what you charge for the medical program. You do not have to show patients the split. You do have to know it.

Second, reprice the program, not the drug. If the medication becomes a pass-through at something near the direct price, and your fee covers evaluation, labs, titration, and physician access, you have a defensible structure that does not move when Novo Nordisk updates a webpage in January.

Third, treat these patients as the recurring-revenue base they are, because the economics are membership economics. CT Acquisitions' 2026 valuation work puts monthly churn in this category at 5 to 10 percent, which produces a patient lifetime of roughly 10 to 20 months. A weight-loss patient who stays fourteen months at a real program fee is worth considerably more than one who buys three months of discounted vials and leaves, and buyers pay for the first kind of revenue at a different multiple than the second.

Fourth, say the difference out loud in your marketing. Not as a claim that you are better, which every practice says. As a specific description of what the mail-order box does not contain: the labs, the titration, the contraindication screening, the person who answers when week three goes badly. Patients cannot choose a difference nobody described to them, and right now most practices are competing on a price comparison they have already lost instead of on a service comparison they would win.

Sources and limits. Self-pay pricing figures are from Novo Nordisk's NovoCare pharmacy savings page, first read on August 31, 2026 and re-read on September 3, 2026; between those two reads the 4 mg oral dose moved from $149 to $199, which is the argument of this piece in miniature. That page states its own pricing is subject to update after December 31, 2026, so re-check before quoting these numbers later. Discontinuation and titration figures are from Xu Y and colleagues, "Titration and discontinuation of semaglutide for weight management in commercially insured US adults," Obesity (Silver Spring), July 2025, 33(7):1243-1248, doi 10.1002/oby.24315, a retrospective cohort of patients who initiated semaglutide between June 2021 and December 2023. That population is insured, not cash-pay aesthetic, so treat the direction as reliable and the level as indicative rather than as a benchmark for your own panel. The program-design detail is first-party, drawn from the published patient-facing service description of a physician-led practice GrowBien works with in Troy, Michigan. Churn and patient-lifetime figures are from CT Acquisitions' Med Spa and Medical Aesthetic M&A Multiples Report 2026, July 2026, which cites FOCUS Investment Banking, BizBuySell, and AmSpa upstream. I did not find, and therefore do not cite, any credible published benchmark for what independent practices charge for GLP-1 programs.

---

The uncomfortable truth in all of this is that the direct-pricing move did not create a problem. It revealed one. Practices that built weight-loss revenue on medicine are fine, and some of them are better off with a cheaper input. Practices that built it on access were always going to lose that access eventually, because access was never theirs to begin with.

Of the four moves, the fourth is the one practices underinvest in most: describing that difference, out loud and specifically, to patients who are otherwise comparing you against a webpage. A webpage cannot describe what it does not contain. That is the part GrowBien exists to run.